Finland· FI-REL-REL45438
Ofev
A nintedanib product containing nintedanib esylate, registered in Finland by Boehringer Ingelheim International GmbH. The same ATC class is registered in 14 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Nintedanib is registered in 14 of 19 countries.
Countries holding a registration under ATC L01EX09 (nintedanib), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 7 of them publish a price we can compare per daily dose
Nintedanib · ATC L01EX09
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
Price per daily dose
What a daily dose of nintedanib costs, country by country.
Normalised to the WHO defined daily dose (0.38 g), so markets compare like for like.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Nintedanib · price per daily dose (0.38 g)
USD · FX 28 Sept 2026
- US United States$51.13 (acquisition cost)
- CH Switzerland$34.12
The record
At a glance
Fimea (Finland)- Active substance
- Nintedanib esylate
- Manufacturer
- Boehringer Ingelheim International GmbH
- Country
- Finland (FI)
- ATC code
- L01EX09
- ATC class
- Nintedanib
- Defined daily dose
- 0.38 g, O
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 1
1 priced- fi_myyntilupa48427160 x 1EUR 2262.09
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
160 interactions on record for nintedanib.
Graded by severity as the source publishes them — 21 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Nintedanib · interactions on record
160 records
- 21 severe
- 139 moderate
Most severe, free to view
- MipomersenC10AX11severe
- LomitapideC10AX12severe
- DexamethasoneH02AB02severe
- RifampicinJ04AB02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Nintedanib in 7 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaNINTEDANIB ACCORDAccord Healthcare S.L.U., Barcelona
- BelgiumNintedanib Accord 150 mgAccord Healthcare
- IrelandNintedanib Accord 150 mg soft capsulesAccord Healthcare S.L.U.
- SwedenNintedanib Bioglan 150 mg Kapsel, mjukBioglan AB
- NorwayNintedanib ZentivaZentiva k.s.
- United StatesnintedanibGlenmark Pharmaceuticals Inc., USA
- GermanyNintedanib AlAliud Pharma Gmbh
Authorised across Europe · EMA
The same active substance is authorised in 15 EEA countries. Names it is sold under:
- Austria · Nintedanib Accordpharma, Nintedanib Ratiopharm
- Cyprus · Nintedanib Teva
- Germany · Nintedanib Al, Nintedanib Ipf Al
- Denmark · Nintedanib Bioglan, Nintedanib Teva
- Estonia · Nintedanib Stada
- United Kingdom (Northern Ireland) · Nintedanib, Nintedanib Eugia (Uk)
- Hungary · Lunidoc
- Iceland · Nintedanib Demo
- Luxembourg · Nintedanib Teva
- Netherlands · Nintedanib Reig Jofre, Nintedanib Tillomed
- Norway · Nintedanib Zentiva
- Portugal · Nintedanib Bravet, Nintedanib Teva Pharma
- Romania · Gevesla, Nintedanib Teva
- Sweden · Nintedanib Bioglan, Nintedanib Teva Gmbh
- Slovakia · Gevesla
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ce0a9e20-25e2-40aa-a40c-3dc546de98f5 GET /v1/drugs/ce0a9e20-25e2-40aa-a40c-3dc546de98f5?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": "0.38",
"form": "kapseli, pehmeä",
"route": "Suun kautta",
"ddd_unit": "g",
"strength": "150 mg",
"atc_label": "nintedanibi",
"ma_number": null,
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": "EU/1/14/979/003-004",
"fimea_rel_id": "REL45438",
"authorised_at": "2015-01-15"
}See everything about nintedanib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.